PTPN2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL178210	1.00	7/20
SCHEMBL178211	1.00	7/20
Oleanonic Acid (SCHEMBL246220)	1.00	7/20
SCHEMBL127553	0.62	7/20
Oleanolic_Acid (SCHEMBL71070)	1.00	4/20
Echinocystic Acid (SCHEMBL42864)	0.75	4/20
Primulagenin (SCHEMBL179854)	0.63	4/20
SCHEMBL264555	0.54	4/20
SCHEMBL264813	0.51	4/20
SCHEMBL40166	0.47	4/20
SCHEMBL69699	0.43	4/20
SCHEMBL278501	0.39	4/20
SCHEMBL97998	0.60	3/20
SCHEMBL97543	0.56	3/20
SCHEMBL148417	0.55	3/20
SCHEMBL17051	0.55	3/20
SCHEMBL95649	0.55	3/20
SCHEMBL95092	0.53	3/20
SCHEMBL95378	0.52	3/20
SCHEMBL96292	0.52	3/20

Clinical trials — most relevant to PTPN2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation	PHASE2	UNKNOWN
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Cyclosporine For The Treatment Of COVID-19(+)	PHASE2	COMPLETED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer	PHASE2	RECRUITING
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease	PHASE2	COMPLETED
Immunoregulatory Therapy for 2019-nCoV	PHASE2	UNKNOWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma	PHASE2	UNKNOWN
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors	PHASE1	RECRUITING
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers	PHASE1	COMPLETED
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)	PHASE1	COMPLETED
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency	PHASE1	RECRUITING
Palliative Thoracic Radiotherapy Plus BKM120	PHASE1	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms	nan	NOT_YET_RECRUITING
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment	nan	NOT_YET_RECRUITING
rT3 and Inflammation in Hashimoto's Thyroiditis	nan	COMPLETED
Resistance to Immunotherapy in Gastric Cancer	nan	UNKNOWN
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure	nan	UNKNOWN
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children	nan	NOT_YET_RECRUITING
What is the Impact of TKI on Thyroid Function in CML Patients?	nan	NOT_YET_RECRUITING
PCM1-JAK2 in Therapy Related Neoplasms	nan	UNKNOWN
Ibrutinib Adapted to Response in Patients With CLL	nan	UNKNOWN
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PTPN2 binder may also engage these)

Protein	Name	Similarity
P35233	—	0.999	P35233 →
Q06180	—	0.995	Q06180 →
Q9Y216	—	0.961	Q9Y216 →
Q9Z2C9	—	0.958	Q9Z2C9 →
Q5R6F6	—	0.957	Q5R6F6 →
Q9Y217	—	0.956	Q9Y217 →
Q8VE11	—	0.956	Q8VE11 →
Q5F452	—	0.955	Q5F452 →
P35832	—	0.954	P35832 →
MTMR1	Phosphatidylinositol-3-phosphate phosphatase MTMR1	0.951	landscape →
Q9WU22	—	0.950	Q9WU22 →
Q96EF0	—	0.950	Q96EF0 →
PTPN4	Tyrosine-protein phosphatase non-receptor type 4	0.948	landscape →
B0X4T2	—	0.947	B0X4T2 →
Q9Z2C4	—	0.947	Q9Z2C4 →
Q6TEL0	—	0.947	Q6TEL0 →
O82656	—	0.946	O82656 →
Q9UPR0	—	0.946	Q9UPR0 →
Q8K394	—	0.946	Q8K394 →
A0A0G2JXT6	—	0.946	A0A0G2JXT6 →
Q4R3F0	—	0.945	Q4R3F0 →
A0A6I8TCE0	—	0.945	A0A6I8TCE0 →
E9Q4Z2	—	0.945	E9Q4Z2 →
Q9NSV4	—	0.944	Q9NSV4 →
Q6XPS3	—	0.943	Q6XPS3 →
Q5U4T3	—	0.943	Q5U4T3 →
Q86X45	—	0.943	Q86X45 →
A6NI28	—	0.943	A6NI28 →
O70291	—	0.942	O70291 →
Q8BPM2	—	0.942	Q8BPM2 →